Q-omics provides the consensus-scored USP26 profile across patient tissues and cancer cell-line models. USP26 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, USP26 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, USP26 RNA expression shows 6,350 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, COAD, and STAD as cancer lineages where USP26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP26 survival associations across molecular data types. USP26 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP26 RNA expression–survival associations across cancer types. High USP26 expression shows unfavorable associations in BRCA, KIRC, LIHC, ACC and LUSC, but favorable associations in ESCA. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify BRCA as the clearest survival context for USP26 RNA expression.
This table summarizes USP26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for USP26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP26 shows higher tumor expression in COAD, KIRP, READ, UCEC, LUAD and LUSC. The COAD box plot shows higher USP26 RNA expression in tumor versus normal tissue (log2 FC = +0.035, t-test p < 0.001).
This table shows molecular features associated with USP26 in patient tissues and cancer cell lines. In patient samples, USP26 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, USP26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
